New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss : vimarsana.com

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...

Related Keywords

United States , United Kingdom , London , City Of , Moorfields , Ballymena , Switzerland , China , Japan , Ireland , America , Irish , American , Levi Garraway , Nathalie Altermatt , Bruno Eschli , Birgit Masjost , Gerard Tobin , Loren Kalm , Sabine Borngr , Kirti Pandey , Regulatory Agency , National Eye Institute , American Society Of Retina Specialists , Roche Group Media Relations , Drug Administration , Genentech , Head Of Global Product Development , Novartis , Roche Group , Bright Focus Foundation , Lancet Glob Health , European Medicines Agency , Chugai Pharmaceutical Co , European Union , Retina Specialists , Annual Meeting , Chief Medical Officer , Global Product , Disease Activity Criteria , Dosing Interval Assignment , Clinical Trial Patients With , Study Design , Diabetic Retinopathy Symposium , Epiretinal Membrane Formation Over , Late Breaking , Reduces Macular Leakage , Patients With , Causes Rapid , Sustained Intraocular Suppression , Retinal Fluid Control With Faricimab , Rapidly Improves Fluid Parameters , China Subpopulation , Treatment Patterns , Diabetic Macular Edema Treated , Delivery System With Ranibizumab , Continuous Treatment , Additional Results From , Presentation Session , Uveitic Macular Edema , Preliminary Results From , Infectious Diseases , Port Delivery System , Drug Administration Approved , Dow Jones Sustainability Indices , Chugai Pharmaceutical , American Society , Demand Presentation , Virtual Paper , Poster Presentation , States Food , Lancet Glob , Product Characteristics , Markets ,